fda bpc-157 status february 2026 Exciting news for peptides coming out of today's committee hearing! The Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC- 157 to the 503A Bulks List for use in compounding for 2026 FDA Peptide Reclassification |

Poor sleep, sleep apnea, excess abdominal weight, inactivity, and prolonged stress may contribute to hypertension and metabolic risk

Phys Med Biol

To meet the diagnostic criteria for cEDS, a person must meet: Major criterion 1 AND major criterion 2 OR Major criterion 1 AND three or more minor criteria Major Criteria Skin hyperextensibility and atrophic scarring Generalized joint hypermobility Minor Criteria Easy bruising Soft, doughy skin Skin fragility (or traumatic splitting) Molluscoid pseudotumors Subcutaneous spheroids Hernia (or history thereof) Epicanthal folds Complications of joint hypermobility (e.g., sprains, dislocations/subluxations, pain, flexible flatfoot) Family history of a first-degree relative who meets clinical criteria Hypermobility Spectrum Disorders (HSD) HSD in Adults Adults are diagnosed with HSD if they have symptomatic joint hypermobility that cannot be explained by other conditions

This medication must not be stopped suddenly without talking to the doctor.Some common side effects of this medicine include nausea, vomiting, diarrhea, constipation, blurred vision, dizziness, and sleepiness